跳至主要内容
临床试验/NCT00577967
NCT00577967Unknown不适用

Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study

Hospital Authority, Hong Kong1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2005年10月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
发起方
入组人数
80
试验地点
1
主要终点
Subjective measurement of reduction in pruritus

研究概览

简要总结

To investigate using the drug gabapentin to relieve the intense pruritic sensation associated with chronic renal failure patients undergoing peritoneal dialysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

性别
All
接受健康志愿者

入选标准

  • Adult Chinese male and female patients aged > 18 undergoing CAPD for at least 3 months and able to read and understand Chinese
  • Patients experiencing moderate to severe pruritis, defined as persistent, treatment-resistant pruritis considerably impairing sleep or daytime activity. Treatment resistance is defined as no or only partial resolvement of pruritis under current anti-pruritis treatment regimens such as anti-pruritis lotions and anti-histamines.
  • Patients in stable clinical condition in terms of peritoneal dialysis and general health
  • Patients able to understand and answer the SDS questionnaire
  • Patients able to express the sensation of itchiness in the terms of the VAS and the SDS score
  • Patients who are willing to give written informed consent and to participate in and comply with the study protocol

排除标准

  • Patients with a known history of pruritis or dermatologic disease antedating renal failure.
  • Patients with skin disease other than the usual cutaneous findings of uraemia such as xerosis or ecchymosis.
  • Patients under current treatment with systemic steroids
  • Known history of allergy to Gabapentin
  • Those patients already put on anti-convulsants
  • Unable to give written informed consent for the study
  • Pregnancy or female patients of child-bearing age who are unwilling to use contraception
  • Poor drug compliance
  • Known HIV positivity
  • Active neoplastic disease
  • Those who do not want to participate the study

结局指标

主要结局

Subjective measurement of reduction in pruritus

时间窗: 3 months

次要结局

  • Tolerability of Gabapentin in CAPD patients(3 months)

研究者

发起方
Hospital Authority, Hong Kong
申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验